Inclusion Criteria:  Subjects who signed the informed consent to participate in the STS-BDB001-06 clinical study and completed all follow-up of the study as required by the protocol, or who withdrew early due to treatment failure or other objective reasons and completed the early withdrawal visit (at least 4 weeks of treatment)  Exclusion Criteria:  Never participated in the clinical study of STS-BDB001-06； Subjects withdrew from the STS-BDB001-06 clinical study due to an intolerable adverse event related to the study drug.